Cowen Maintains Buy on Regeneron Pharmaceuticals, Inc. (REGN) March 2026

NodeGuardian · 2026-03-11T07:08:35+00:00

Cowen & Co. maintained a Buy rating for Regeneron Pharmaceuticals (REGN) on March 9, 2026, citing potential for preferential prescribing, leading to a 2.29% stock increase. Meyka AI also gives REGN an A grade for strong performance.

NodeGuardian

2026-03-11 07:08:35

Abstract generation in progress

Cowen & Co. reaffirmed its Buy rating for Regeneron Pharmaceuticals, Inc. (REGN) on March 9, 2026, based on the potential for preferential prescribing if U.S. clinical results are replicated. This maintained rating, without a new target price, was met with a modest 2.29% stock rise, signaling investor confidence but not a new catalyst. Meyka AI also rates REGN with an A grade, indicating strong performance relative to benchmarks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.